Group 1: Investment Opportunities - The article highlights three stocks that are considered attractive investment opportunities before the end of 2024, particularly as they are currently priced at a discount from their highs [2][3]. Group 2: The Coca-Cola Company - The Coca-Cola Company has experienced a 1% decline in drink sales compared to the same quarter last year, leading to a 14% drop in stock price from its peak in September [3][4]. - Despite recent challenges, Coca-Cola is viewed as a steady grower with a reliable earnings engine, having raised its annual dividend for 62 consecutive years [5][6]. - The company's market dominance and brand recognition contribute to its long-term success, making the recent stock decline an attractive buying opportunity [6]. Group 3: Uber Technologies - Uber Technologies reported 161 million rides last quarter, generating $11.2 billion in revenue, marking a year-over-year increase of 13% and 22% respectively [7][8]. - Analysts project Uber's revenue to grow by 17% this year and nearly 16% next year, with the global ride-hailing market expected to grow over 11% annually through 2032 [9][10]. - The company is now consistently profitable, with earnings per share expected to rise from $0.87 last year to $1.89 this year, and further to $2.31 next year [10][11]. Group 4: Iovance Biotherapeutics - Iovance Biotherapeutics is a biopharma company with its flagship drug, Amtagvi, recently receiving FDA approval, although its stock has declined over 50% since the approval [12][14]. - Expected revenue for Iovance is projected to be between $160 million and $165 million for the current fiscal year, with growth anticipated to reach $450 million to $475 million next year [15]. - The company is on track to potentially achieve profitability by 2027, with ongoing trials for Amtagvi indicating a possibility of exceeding $1 billion in annual revenue by 2030 [16].

Industry Overview - The biotech industry is characterized by high risk and high reward, with some companies achieving significant success while many startups fail [1] - The potential for massive shareholder wealth exists if a company develops a blockbuster drug [1] Company Overview - Iovance Biotherapeutics is an emerging leader in the biotech industry with significant potential due to its tumor-infiltrating lymphocyte (TIL) therapy [2] - The company's TIL therapy, Amtagvi, is a revolutionary treatment for a wide range of cancers, particularly advanced melanoma [4][5] - Iovance has transitioned from a clinical-stage biotech to launching a novel therapy into the market, marking a critical step in its development [9] Product and Pipeline - Amtagvi is the first-of-its-kind cellular therapy approved for solid tumor cancers and advanced melanoma, with a unique mechanism of action that enhances the body's natural cancer-fighting response [4][5] - The therapy involves harvesting T cells from the patient's tumor, manufacturing a personalized TIL monotherapy, and returning it to the patient as a one-time intravenous infusion [6] - Clinical data has shown impressive results, with long-lasting responses and the ability to prevent cancer progression in advanced melanoma patients who failed other immunotherapies [6] - The initial addressable market is estimated at 30,000 patients annually, with potential expansion to over 70,000 patients through an expanded label indication [7] - The pipeline includes lifileucel applications in phase 2 studies for non-small cell lung cancer (NSCLC) and longer-term development in endometrial cancer [8] Financial Performance - Iovance generated $59 million in revenue in the third quarter, a significant increase from under $500,000 in the prior-year quarter, driven by Amtagvi's adoption [10] - Full-year 2024 revenue is expected to be between $160 million and $165 million, with a target range of $450 million to $475 million in 2025, the first full year of Amtagvi sales [11] - Wall Street analysts project a loss of $1.30 per share in 2024, narrowing to a loss of $0.82 per share in 2025, with profitability remaining elusive due to ongoing R&D and global expansion costs [11] Growth Potential and Risks - Iovance shows promise in the early stages of a major growth opportunity, with potential to evolve into a multi-bagger stock [13] - The company needs to demonstrate an ability to enter new oncology categories beyond melanoma to sustain growth [14] - Market focus on metrics like margins and cash flow, along with the possibility of disappointing clinical data, could pose financial headwinds and keep shares volatile [12] Investment Consideration - Iovance deserves to be on investors' radar due to its promising developments and potential for significant returns [14] - Investors confident in the company's outlook might consider initiating a small position within a diversified portfolio [14]

Core Insights - Iovance Biotherapeutics has promoted Raj Puri, M.D., Ph.D. to the newly created role of Chief Regulatory Officer, highlighting his significant contributions to the company's regulatory strategy and product pipeline [1][2] Company Overview - Iovance Biotherapeutics focuses on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, aiming to be a global leader in this field [4] - The company’s product, Amtagvi™, is the first FDA-approved T cell therapy for a solid tumor indication, with plans to address over 20,000 patients annually with advanced melanoma starting in 2025 [2][4] Leadership and Experience - Dr. Raj Puri has over 33 years of experience at the FDA, where he held various positions, including director of the Division of Cellular and Gene Therapies, and has been instrumental in the regulatory approval processes for Iovance's products [2][3] - His expertise includes advanced therapies such as cell and gene therapy, cancer vaccines, and cellular immunotherapy, which are critical for Iovance's ongoing product development [2][3] Product Pipeline and Future Prospects - Iovance is advancing its product pipeline, including lifileucel for non-small-cell lung cancer and endometrial cancer, with multiple regulatory milestones expected in 2025 [2] - The company is committed to continuous innovation in cell therapy, including gene-edited cell therapy, to improve patient outcomes [4]

Core Viewpoint - Iovance Biotherapeutics is positioned as a leading player in the cell therapy biotech sector, with its product Amtagvi showing strong sales potential and growth prospects [1][2]. Group 1: Market Growth - Iovance's first approved cell therapy, Amtagvi, is projected to generate at least $160 million in revenue this year, with expectations to reach at least $450 million by 2025, indicating a potential tripling of revenue in the near term [4]. - The total addressable market for Amtagvi is estimated to be between 20,000 and 30,000 patients annually, with plans to expand the network of authorized treatment centers (ATCs) to 70 in the U.S. by year-end [6]. Group 2: Manufacturing Expansion - The company is expanding its manufacturing capacity to produce doses for approximately 5,000 patients annually and is establishing a network of contract manufacturers to potentially treat an additional 15,000 patients per year [7]. - Successful manufacturing expansion could enhance Iovance's margins by controlling costs and may allow for licensing its facilities to other biopharma companies [8]. Group 3: Research and Development - Ongoing R&D efforts aim to explore additional indications for Amtagvi, potentially increasing the total addressable market to 70,000 patients globally, which would require further manufacturing investments [9]. - A critical phase 3 clinical trial is currently assessing the use of Amtagvi as a first-line treatment alongside pembrolizumab, which could accelerate therapy adoption [10]. Group 4: Regulatory Outlook - Iovance is seeking regulatory approvals for Amtagvi in Australia, Switzerland, Canada, the U.K., and the E.U. next year, presenting multiple catalysts for future revenue growth [11]. Group 5: Long-term Growth Potential - As global access to Amtagvi increases, the company has significant growth opportunities, supported by a strong start in the therapy's commercialization [13].

Group 1 - The group caters to both novice and experienced biotech investors, providing insights on catalysts, buy and sell ratings, and product sales forecasts for major pharmaceutical companies [1] - The group offers integrated financial statements, discounted cash flow analysis, and market-by-market analysis [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the investing group Haggerston BioHealth and has compiled detailed reports on over 1,000 companies [1]

Iovance Biotherapeutics, Inc. (IOVA) incurred a third-quarter 2024 loss of 28 cents per share, narrower than the Zacks Consensus Estimate of a loss of 31 cents. In the year-ago quarter, the company reported a loss of 46 cents.During the quarter, the company generated total revenues of $58.6 million, entirely from the product sales of its two marketed drugs. The reported sales beat the Zacks Consensus Estimate of $53.5 million. In the year-ago quarter, Iovance recorded total revenues of $0.5 million.More on ...

Financial Data and Key Metrics - Q3 2024 total product revenue was $58.6M, exceeding the guidance range of $53M-$55M, driven by $41M from Amtagvi and $16.5M from Proleukin [9] - Year-to-date total product revenue through September 30, 2024, was $90.4M, including $54.9M from Amtagvi and $35.5M from Proleukin [10] - Net loss for Q3 2024 was $83.5M ($0.28 per share), compared to a net loss of $113.8M ($0.46 per share) in Q3 2023 [40] - Gross margin improved to $25.6M in Q3 2024, positioning the company more than halfway toward the target of over 70% gross margin in the coming years [49] Business Line Data and Key Metrics - Amtagvi revenue is recognized upon patient infusion, while Proleukin revenue is recognized upon delivery to distributors or hospitals [10] - 146 patients have been infused with Amtagvi since April, with 25 in Q2, 82 in Q3, and 39 in Q4 to date, reflecting increasing adoption rates [11][12] - The company has 56 authorized treatment centers (ATCs) and aims to onboard approximately 70 ATCs by year-end 2024 [12] Market Data and Key Metrics - Approximately 75% of Amtagvi patients are covered by private payers, with over 250M lives (95% of U S covered lives) having access to reimbursement [13][14] - The company is targeting global markets, with potential first ex-U S approval in H1 2025 and EU approval in H2 2025 [20][21] - Amtagvi represents a multibillion-dollar opportunity globally, addressing over 20,000 advanced melanoma patients annually in the U S and initial ex-U S markets [18] Company Strategy and Industry Competition - The company is focused on expanding its ATC network, improving manufacturing capacity, and optimizing operational efficiencies to meet growing demand [12][29][33] - Future growth drivers include global label expansions in frontline advanced melanoma, other tumor types, and next-generation TIL cell therapies [23] - The company’s intellectual property portfolio includes over 230 granted or allowed patents, providing exclusivity through at least 2042 [37] Management Commentary on Operating Environment and Future Outlook - Management reaffirmed full-year 2024 total product revenue guidance of $160M-$165M and 2025 guidance of $450M-$475M [17] - The company expects significant revenue growth in 2026 and beyond, with Amtagvi and Proleukin representing a $1B+ peak opportunity in the U S market alone [18] - Management highlighted strong demand, favorable payer coverage, and operational improvements as key drivers of future growth [12][17][33] Other Important Information - The company is advancing its clinical pipeline, including trials in non-small cell lung cancer, frontline melanoma, and endometrial cancer [56][64][68] - Next-generation programs, such as IOV-4001 (PD1-inactivated TIL) and IOV-5001 (IL-12 TIL), are under development to enhance efficacy and safety [69][73] - The company is expanding manufacturing capacity, with plans to increase annual capacity to over 10,000 patients through facility expansion and process optimization [35] Q&A Session Summary Question: Impact of holidays on Q4 infusions - Management expects a lull during holidays but remains confident in meeting annual guidance, with infusions projected to continue growing [79][80] Question: IL-2 stocking levels - Proleukin stocking levels are expected to stabilize after Q4 2024, with growth anticipated to follow a more traditional quarter-over-quarter pattern in 2025 [81][82][83] Question: Preconditioning practices - Larger ATCs with more experience are increasingly comfortable initiating preconditioning before Amtagvi arrival, reflecting confidence in manufacturing success rates [85][86][87] Question: Monthly infusion growth trajectory - Infusions grew month-over-month in Q3, driven by ATC expansion and improved manufacturing capacity, with continued growth expected in Q4 [90][91][92] Question: Gross margin improvement - Gross margin improvements are driven by increased capacity utilization, operational efficiencies, and cost optimization initiatives, with a target of over 70% in the coming years [95][96][97] Question: Dropout rate improvements - Dropout rates improved due to optimized launch processes, better patient selection, and surgical resection quality, with further improvements expected as the launch matures [100][101] Question: Reimbursement and lung cancer trial - Reimbursement clearance time has improved to three weeks, and the company expects data from the lung cancer trial in 2025, with potential approval in 2027 [104][105][107] Question: Out-of-spec rate trends - Out-of-spec rates are improving due to ATC experience and better patient selection, with new ATCs benefiting from early learning and peer-to-peer support [109][110][111]

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.46 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9.68%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.37 per share when it actually produced a loss of $0.34, delivering a surprise of 8.11%.Over the last four quarters, the ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-36860 IOVANCE BIOTHERAPEUTICS, INC. (Exact name of issuer as specified in its charter) Delaware 75-3254381 (State or o ...

Exhibit 99.1 Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024 Significant Demand for Amtagvi™ (Lifileucel) Continues with $58.6M in Total 3Q24 Product Revenue Reaf irming Guidance of $160-$165M for FY24 and $450-$475M for FY25 of Total Product Revenue Marketing Authorization Applications Validated and Accepted for Review by European Regulatory Authorities for Potential Approval Starting with the UK in 1H2025 and EU and Canada in 2H2025 Enrollmen ...